QC
SGMT icon

Quadrature Capital’s Sagimet Biosciences SGMT Stock Holding History

Quadrature Capital’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$368K Buy
+47,604
New +$324K ﹤0.01% 1130

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
FRM
Fox Run Management Greenwich, Connecticut $603M AUM 32% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Quadrature Capital's SGMT Position: Q2 2026 in Review

Quadrature Capital opened a new position in Sagimet Biosciences (SGMT) in Q2 2026: 47,604 shares worth $368K. The stake represents ﹤0.01% of the portfolio and ranks #1130 among its holdings.

29 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Quadrature Capital held 47,604 shares of Sagimet Biosciences worth $368K as of Q2 2026.
  • Sagimet Biosciences was a new Quadrature Capital position in Q2 2026.
  • Sagimet Biosciences made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1130 holding.
  • 29 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.